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Abstract
Background: A small number of recent reports have suggested that altered placental DNA methylation may be associated
with early onset preeclampsia. It is important that further studies be undertaken to confirm and develop these findings. We
therefore undertook a systematic analysis of DNA methylation patterns in placental tissue from 24 women with
preeclampsia and 24 with uncomplicated pregnancy outcome.
Methods: We analyzed the DNA methylation status of approximately 27,000 CpG sites in placental tissues in a massively
parallel fashion using an oligonucleotide microarray. Follow up analysis of DNA methylation at specific CpG loci was
performed using the Epityper MassArray approach and high-throughput bisulfite sequencing.
Results: Preeclampsia-specific DNA methylation changes were identified in placental tissue samples irrespective of
gestational age of delivery. In addition, we identified a group of CpG sites within specific gene sequences that were only
altered in early onset-preeclampsia (EOPET) although these DNA methylation changes did not correlate with altered mRNA
transcription. We found evidence that fetal gender influences DNA methylation at autosomal loci but could find no clear
association between DNA methylation and gestational age.
Conclusion: Preeclampsia is associated with altered placental DNA methylation. Fetal gender should be carefully considered
during the design of future studies in which placental DNA is analyzed at the level of DNA methylation. Further large-scale
analyses of preeclampsia-associated DNA methylation are necessary.
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Introduction
Preeclampsia is a hypertensive disorder that affects 5–7% of all
pregnancies and is one of the major obstetrical complications
resulting in fetal morbidity and mortality [1]. It is defined by
maternal arterial pressure .140/90 mmHg and proteinuria .
300 mg/dL/24 h after 20 weeks gestation. Although preeclampsia
is a complex phenotype with underlying pathobiology that likely
involves multiple systems in both mother and fetus, it is thought to
be partly caused by disruption or alteration of the highly regulated
and ordered processes underlying trophoblast invasion and
placentation. The result of this is that placentas from preeclamptic
pregnancies are poorly perfused due to inadequate remodeling of
the spiral arteries [2,3,4].
Numerous studies have identified altered gene expression in the
placentas of mothers affected by preeclampsia [5,6,7,8,9].
Preeclampsia-specific altered gene expression has also been
reported in chorionic villus samples obtained in early gestation
from pre-symptomatic mothers who went on to develop
preeclampsia [10,11]. Furthermore, it has also been shown that
alterations in expression patterns are not confined to the placenta
and can be observed in circulating maternal white blood cell
populations [12].
Although the relationship between DNA methylation and gene
expression at the level of transcription is complex, there is strong
evidence that altered DNA methylation, particularly within the
regulatory regions of expressed genes, has a significant influence
on transcription [13,14,15]. Given the strong evidence that gene
expression is altered in preeclamptic pregnancies, it is reasonable
to hypothesize that preeclampsia may also be associated with
altered DNA methylation in key regulatory regions. Indeed, in
2010, it was reported that early onset (,34 weeks gestation), but
not late onset (.34 weeks gestation), preeclampsia is associated
with altered DNA methylation [16]. This study was somewhat
limited by the number of individuals (n = 4 per group) that were
analyzed. In a more recent larger study the same group found that
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DNA methylation is altered in placental samples from individuals
suffering with early onset preeclampsia (EOPET) when compared
to gestational age-matched karyotypically normal samples ob-
tained from women who suffered pregnancy loss or early labor for
a variety of reasons [17].
Given our relatively limited understanding of epigenetic
alterations in preeclampsia, it is important that further studies
are undertaken so that reported associations between DNA
methylation and preeclampsia may be verified and expanded
upon. Therefore we have undertaken an analysis of DNA
methylation in the context of preeclampsia using a commercially
available microarray that is able to simultaneously assess DNA
methylation levels at 27,000 CpG dinucleotides.
Materials and Methods
Samples
All patients provided written informed consent for use of their
samples and de-identified clinical data under the umbrella of the
Preeclampsia Program Project (PEPP study) and related ancillary
studies. These women delivered at Magee-Womens Hospital
within the years 1997–2007, and were recruited from clinics and
private practices. This protocol was approved by the University of
Pittsburgh Institutional Review Board (Protocol # IRB 0404159).
Clinical and demographic characteristics of the individuals
recruited to take part in this study are shown in Table 1.
A panel of clinicians met monthly to adjudicate the pregnancy
outcome diagnosis of all the women. Preeclampsia was defined as
gestational hypertension with proteinuria in accordance with the
National High Blood Pressure Education Program Working
Group Report on High Blood Pressure in Pregnancy [18].
Gestational hypertension was defined as persistent, new onset
hypertension (systolic $140 mm Hg and/or diastolic $90 mm
Hg) appearing after 20 weeks’ gestation. Proteinuria was defined
as $300 mg of protein in a 24 hour urine collection, a dipstick of
2+, a catheterized sample of 1+, or protein:creatinine $0.3. To
ensure that preeclamptic women had the specific disease of
interest, our research definition also required gestational hyper-
uricemia ($1 standard deviation above reference values for the
gestational age (e.g. term, .5.5 mg/dL)) [19]. Hyperuricemia is
thought to minimize the number of women with hypertension in
pregnancy who are misclassified as preeclamptics [20]. Women
with uncomplicated (‘‘normal’’) pregnancy were normotensive and
without proteinuria throughout gestation, and delivered healthy
babies in the absence of infection.
All participants had no prior history of renal or vascular disease,
and were non-smokers (,100 cigarettes in lifetime). Status of
tobacco smoking was determined by self-report; these data were
obtained during the pregnancy or immediately postpartum to
minimize the potential problems caused by changing smoking
habits during pregnancy. In a previous study of our patient
population, there was no significant discordance between self-
report of smoking status and maternal plasma cotinine concen-
tration using a cutoff value of $2.0 ng/ml (P= 0.49), with 82%
agreement and k coefficient of 0.64 [21]. Pre-pregnancy weight,
self-reported at enrollment, and measured height were used to
calculate pre-pregnancy body mass index (BMI; weight
[kg]/height [m2]). Maternal race was by self-report at enrollment.
Placental biopsies were obtained immediately after delivery
from the maternal side of the placenta, in regions free of infarcts
between the placental margin and cord insertion. Decidua was
removed by blunt dissection. The tissue was immediately
transported in saline to the laboratory, flash frozen in liquid
nitrogen and stored at 280uC for later use.
DNA Isolation
To isolate DNA, 180-mL buffer ATL (from Qiagen’s DNeasy
Blood and Tissue kit, Qiagen, Valencia, CA) and a 5-mm steel
Table 1. Sample Demographics and Clinical Characteristics.
Normal pregnancy (n =24) Preeclamptic pregnancy (n =24) P-value
Maternal age (years) 29.365.4 27.967.2 0.549
Gestational age at delivery (weeks) 39.361.2 35.064.0 ,0.001*
Maternal race (n, %)
White 21 (86.3%) 19 (79.2%) 0.589
African-American 3 (13.7%) 4 (16.7%)
Other 0 (0.0%) 1 (4.2%)
Nulliparous (n) 23 24 0.289
Pre-pregnancy BMI 24.164.5 25.364.0 0.21
Systolic BP,20 weeks (mm Hg) 114.168.0 118.2610.4 0.115
Diastolic BP,20 weeks (mm Hg) 69.565.5 71.166.5 0.242
Systolic BP at delivery (mm Hg) 122.6611.3 152.068.6 ,0.001*
Diastolic BP at delivery (mm Hg) 73.369.3 96.267.9 ,0.001*
Proteinuria (n) 0 24 ,0.001*
Uric acid (mg/dL) ND 6.260.9
Cesarean delivery (n, %) 15 (62.5%) 15 (62.5%) 1.0
Birth weight (g) 32288.16588.6 2314.861121.8 0.002*
Birth weight centile (%) 49.3630.6 34.4628.9 0.095
Female baby gender (n, %) 13 (54.2%) 10 (41.7%) 0.56
Data presented as Mean 6 Standard Deviation as marked.
ND = not determined.
doi:10.1371/journal.pone.0107318.t001
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bead were added to each placenta sample. The samples were then
homogenized in a TissueLyser (Qiagen) for 20 s at 30 Hz. The
DNA was then purified using the DNeasy Blood and Tissue kit as
per the manufacturer’s protocol.
Infinium Microarray Analysis and Determination of
Methylation Status
DNA samples were prepared for microarray analysis and
methylation status determined as previously described (Bunce, et
al, 2012). P values were adjusted using Benjamini and Hochberg’s
method to control the false discovery rate (FDR) at 10%. DNA
methylation data has been deposited at the Gene Expression
Omnibus repository (GE59274).
Targeted Bisulfite Sequencing
DNA was bisulfite converted using Zymo’s EZ DNA Methyl-
ation Gold kit as per manufacturer’s protocol (Zymo Research,
Irvine, CA). Bisulfite specific primers were designed using
Methprimer (www.urogene.org/methprimer) or BiSearch
(http://bisearch.enzim.hu). PCR products were amplified as
separate reactions using Pfu Turbo Cx (Agilent Technologies,
Santa Clara, CA), Platinum Taq (Life Technologies, Carlsbad,
CA) or ZymoTaq (Zymo Research). Primer sequences, melting
temperatures (Tm) and cycling conditions are shown in Tables
S1A and S1B in File S1. Each amplicon was visualized on a 2%
agarose gel. Amplicons were pooled by sample by volume and
pools were purified using Agencourt AMPure XP Beads (Beckman
Coulter, Brea, CA) per manufacturer’s protocol. Sample pools
were run on Bioanalyzer to confirm appropriate size distribution
and sufficient quantity of DNA for library prep. Libraries were
prepared using Illumina’s TruSeq DNA Sample Prep Kit and
sequenced on a HiSeq 2500 as per manufacturer’s protocols
(Illumina, San Diego, CA).
Sequenom Epityper/Quantitative Methylation Analysis
Quantitative Methylation Analysis was performed as previously
described [22]. Primer sequences are presented in Table S1C in
File S1.
Statistical Analysis
We compared the% methylation between cases versus normal
pregnancy controls or samples from normal pregnancies involving
males versus female offspring, and P-values were adjusted using
the false discovery rate. Adjusted p-values less than 0.1 were
considered statistically significant.
Hierarchical Clustering and Multidimensional Scaling
We applied two different types of unsupervised learning
algorithms (agglomerative hierarchical clustering and multi-
dimensional scaling) on the methylation data to visualize the
similarity of the methylation profiles across the samples. For
hierarchical clustering, we used the Ward’s minimum variance
method, and chose respectively the Euclidean distance between
the methylation rate of all probes, as well as 1– Pearson’s
correlation between the log ratio of the signal B to signal A of all
probes, as the distance between two samples. The same two types
of distance metric were also used in the multi-dimensional scaling
analysis of the methylation data. Both types of unsupervised
learning analyses were performed using the statistical computing
program R.
Results
Patient demographics
The clinical and demographic data for the 48 subjects who
provided placental samples are presented in Table 1. As expected
based on definitions, women with preeclampsia had proteinuria,
elevated uric acid, and higher systolic and diastolic blood pressures
at delivery. Maternal age, race, parity (1 uncomplicated pregnancy
was multiparous), mode of delivery and blood pressure before 20
weeks were not statistically different between the groups. Overall,
the gestational age at delivery for preeclamptic women was
significantly lower than the uncomplicated pregnancy group.
Infant birth weights were significantly lower in the preeclamptic
group. Birth weight percentiles were lower, but not significantly so,
compared to controls.
Placental Methylation Signatures Correlate Strongly With
Fetal Gender
We first compared DNA methylation patterns in placental tissue
samples from preeclampsia cases with normal controls by Infinium
microarray. This identified a small number of differentially
methylated CpG sites (Table S2A and S2B in File S1), the
majority of which were hypomethylated in preeclampsia samples.
We then performed an unsupervised hierarchical clustering
analysis of all data with the goal of identifying patterns of
methylation between sub-groups of preeclampsia and normal
control samples. This revealed that DNA methylation was strongly
associated with fetal gender irrespective of disease state (Figure 1).
This finding strongly influenced subsequent analysis of our data in
that we controlled for the influence of fetal gender either by
analyzing male and female samples separately or by excluding X-
chromosome specific probes as described below.
Fetal Gender-Dependent Preeclampsia-Associated
Changes in Placental DNA Methylation
Based upon the above findings we reanalyzed our data by
considering pregnancies involving male and female fetuses
separately. This resulted in the identification of a considerably
larger number of differentially methylated loci when FDR was
controlled at 10%. CpG sites with statistically significant
differences of .10% methylation between preeclampsia and
control samples are shown in Tables 2 and 3. (Note that
statistically significant differences of ,10% methylation between
preeclampsia and control samples are shown in S3A and S3B).
These differences were only found in samples from pregnancies
in which the fetal gender was female. All significant differentially
methylated sites involved changes in the frequency of methylated
CpG sites of ,20%. No significant differentially methylated CpG
sites were found in placentas from pregnancies where the fetal
gender was male. These results were confirmed for a subset of
CpG sites in distinct genes by Sequenom Epityper analysis and
high-throughput bisulfite sequencing (Figure 2). Notably, a num-
ber of these sites were significantly differentially methylated in
samples of both fetal genders when single CpG loci were analyzed
in this fashion (Figure 2).
DNA Methylation is Altered in Early Onset Preeclampsia
Previous studies have reported that significant differences in
DNA methylation exist in placental tissue from mothers with
EOPET (,34 weeks gestation) when compared to normal controls
who delivered at term. These previous studies, which controlled
for gender bias by removing all X chromosome data points prior
to analysis, reported no differences when comparing late onset
Analysis of Placental DNA Methylation in Preeclampsia
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preeclampsia samples (.34 weeks gestation) with normal preg-
nancy controls. To be consistent with these previous study designs
we therefore reanalyzed our data, after excluding X chromosome-
specific probe results, to compare EOPET (n= 9) samples with all
normal controls (n = 24). As shown in Table 4 (and S4A in File
S1), we identified 49 CpG sites whose methylation levels are
significantly altered in placental tissue from EOPET cases versus
normal controls when FDR is controlled at 10%. We found far
more CpG sites (78%) that were hypomethylated in EOPET
samples when compared to normal controls than visa versa. Of the
genes identified as being differentially methylated between
EOPET and controls, 28 overlapped with those listed in Tables 2
and 3. Differentially methylated CpGs, albeit far fewer, were also
identified when comparing late onset samples with controls
(Table 5). We also performed similar analyses in a gender-
dependent fashion. Specifically, EOPET samples were compared
with normal controls and pregnancies involving female and male
fetuses were analyzed separately. Using this approach we found
only minimal overlap (3 sites out of a possible 24) between
significantly altered CpG sites in pregnancies involving male
versus female fetuses. Gender-dependent differences in methyla-
tion patterns were also observed between late onset preeclampsia
cases and controls but only in pregnancies involving female (and
not male) fetuses (Table S4B in File S1).
Gestational Age does not Substantially Influence DNA
Methylation
Given previously published evidence that gestational age at time
of delivery is a major contributor towards altered DNA
methylation [16,17], we directly compared preeclampsia placental
samples obtained at delivery before and after 34 weeks gestation
after removal of X chromosome-specific probe data. Only a single
CpG site, MC1R, was found to be differentially methylated
between ,34 and.34 week samples with FDR controlled at 10%.
Hierarchical clustering supported this finding and multidimen-
sional scaling (MDS) analyses that showed no clear evidence of
clustering of early versus late onset preeclampsia samples (Figure
S1). A similar lack of gestational age-related clustering was also
observed when normal controls were analyzed alone (not shown).
Taken together these findings indicate minimal impact of
gestational age at delivery, within the third trimester, on DNA
methylation.
Lack Correlation Between Gene Expression and DNA
Methylation in EOPET
Given the fact that changes in DNA methylation within gene
regulatory sequences are known to influence gene expression, we
analyzed a publicly available gene expression microarray data set
in which placental tissue samples from pregnancies affected with
EOPET were compared to normal control tissues (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?targ=self &form=html&view
= quick&acc =GSE44711). We hypothesized that reduced CpG
methylation in a given sample cohort (preeclampsia or control)
identified in our own data would correlate with an increase in
transcription. We could find no overlap between genes containing
differentially methylated CpG sites (Table S4A in File S1) and
genes whose expressions were significantly altered (Table S7 in File
S1) (adjusted p value of ,0.1 and log2 ratio.1) when comparing
EOPET samples with controls. It should be noted, however, that
gene expression and DNA methylation analyses were not
Figure 1. Hierarchical Clustering of all DNA Methylation Data. Samples marked with ‘‘P’’ and ‘‘N’’ represents ‘‘normal’’ and ‘‘preeclampsia’’
samples respectively. Samples marked with black and grey boxes are from pregnancies in which the fetus was male and female respectively. Data
points from all chromosomes were included.
doi:10.1371/journal.pone.0107318.g001
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performed on the same samples but, rather, phenotypically similar
(EOPET) samples.
Differentially Methylated Genes are not Strongly
Correlated Between Independent Studies
When comparing CpG sites whose methylation patterns are
altered in preeclampsia versus normal controls, we found very
minimal overlap between our own results and those that have been
previously published [16,17]. This was the case regardless of how
gender bias was controlled (either by treating male and female
pregnancies separately or removing X chromosome data points).
Specifically, in 2010, Robinson et al. [16] reported 34 differentially
methylated CpG sites when comparing 4 normal with 4 EOPET
tissue samples using the Humanmethylation27 Infinium micro-
array. In a larger study, the same group reported 282 differentially
methylated CpG sites within 248 distinct genes when similar
comparisons were made [17]. In our analysis of EOPET samples
versus normal controls we could find only 1 (CHI3L2) and 2
(PAPPA2 and DAPK3) genes, respectively, that overlapped with
these genes identified in these studies [16,17]. Notably, direct
comparison between these two previous data sets resulted in the
identification of only 2-shared CpG sites in 2 distinct genes (MEST
and TIMP3). Furthermore, we could find only 5 genes (DAPK3,
DUSP1, PAPPA2, ITCH, DENND2D) that overlapped with our
gender-specific analysis of our data of all early and late combined
preeclampsia samples (Tables 2 and 3).
Gender-Specific Differences in Placental DNA
Methylation Provide Positive Control Data
Given the lack of correlation between independent studies and
the relatively modest differences in methylation frequency at
specific loci in our data, we compared male versus female
pregnancies with the goal of identifying X chromosome-specific
alterations in DNA methylation associated with dosage compen-
sation and X inactivation. We anticipated that X chromosome-
specific probes could effectively serve as positive controls to
establish the sensitivity of the microarray platform. As predicted by
the clustering data shown in Figure 1, we identified numerous
differentially methylated sites on the X chromosome regardless of
whether male versus female comparisons concerned normal or
preeclampsia samples. A subset of these gender-specific methyla-
tion differences was confirmed by Sequenom Epityper analysis,
and a further subset was confirmed by high-throughput targeted
bisulfite sequencing (Figure 3). A number of gender-specific
differentially methylated CpG sites were also found on autosomes
(Table S8A and S8B in File S1). These differences were generally
quite small but this finding supports the fact that male and female
samples can be broadly separated by unsupervised hierarchical
clustering and multidimensional scaling when analyzing both
preeclampsia samples (Figures S2A and S2B) and normal controls
(Figures S2C and S2D).
Reanalysis of Previously Published Data Reveals Impact
of Statistical and Bioinformatic Methods
The lack of overlap between genes identified in the current
study and previously published reports may either be the result of
biological variation, study design and/or statistical analysis of data.
We therefore downloaded raw data from one of these manuscripts
and re-analyzed it using our own statistical pipeline to test whether
fundamental differences in analytical approach can dramatically
influence results. Of 248 distinct genes identified previously [17]
only 56 were found to overlap with CpG sites whose altered DNA
methylation was statistically significant in our analysis of the same
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data (Table S5A in File S1). Additionally, we identified CpG sites
within 75 distinct genes that were not identified in the original
study (Table S5B in File S1). Notably, when we compared two
previously published data sets that compared placental tissue from
EOPET with normal controls [16,17] we found only 3 genes
whose DNA methylation patterns were identified as significant
(TIMP3, MEST and CXCL9) out of a maximum possible 34.
Discussion
In this study, we describe DNA methylation patterns in human
placental tissue samples obtained at birth from both preeclamptic
and normal pregnancies. In addition to identifying disease-specific
alterations in placental methylation, we also identified gender-
dependent changes that are both X-chromosome and autosome-
specific. We could find no correlation between promoter DNA
methylation and gene expression for differentially methylated
CpG sites, although gene expression and DNA methylation
analyses were not performed on the same samples but, rather,
phenotypically similar (EOPET) samples.
Furthermore, we identified a significant lack of correlation
between multiple independent data sets from three separate
studies.
It is notable that we identified minimal overlap between our
data and two previously published studies describing differences
between normal controls and EOPET [16,17]. One reason for this
may be that, to control for the documented influence of tobacco
smoke on DNA methylation, our study used only placental
samples from self-reported non-smokers. This may be significant
given the fact that smoking has been shown to influence DNA
methylation in a variety of contexts [23,24,25,26,27,28,29].
Similarly, given that DNA methylation is also known to be
affected by a variety of environmental stresses [30] the lack of
consistency between independent studies may also be due to other
complex variables. Furthermore, preeclampsia is an extremely
complex syndrome that is classified by gross phenotypic param-
eters. Therefore it is possible that, despite exhibiting similar
clinical characteristics, there are significant phenotypic differences
between the patients in our cohort and those of other studies that
may influence DNA methylation patterns. Furthermore, statistical
methods are likely to influence results such that different
statistically significant CpG sites are identified in the same data
Figure 2. Targeted Analysis of Differentially Methylated Loci in Preeclampsia. Locus-specific analysis of CpG methylation in normal
controls and preeclampsia samples was carried out by Sequenom Epityper (TLE1, IRAK1) (n = 24 controls and n=24 PE samples) or high-throughput
bisufite sequencing (n = 12 controls and n= 12 PE). Samples from pregnancies involving female (left panel) and male (right panel) fetuses were
analyzed separately. Statistically significant differences in% methylation between samples are marked with **. Genomic coordinates corresponding to
values on the x-axis can be found in Table S6A in File S1.
doi:10.1371/journal.pone.0107318.g002
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when different algorithms are used. Indeed the fact that our re-
analysis of existing data resulted in the identification of many new
genes is likely due to the fact that our data were analyzed using the
Limma algorithm and previously published data were analyzed by
SAM. Finally, our control samples, unlike these previous studies,
were not selected from mothers who underwent premature labor
to provide gestational age matching for early onset preeclampsia
cases. We specifically chose not to use premature labor controls to
avoid possible complications of using non-normal samples and
confounding our results. Our approach is supported by our data,
which show no clear association between DNA methylation
patterns and gestational age within the gestational age range (third
trimester) of samples used.
A number of notable differences in DNA methylation of specific
genes were observed in our data. For example, the expression of
Purinergic Receptor P2X, Ligand-Gated Ion Channel, 4 (P2RX4)
has been shown to be elevated in both pre-term and term placental
samples from preeclampsia cases compared to normal controls.
Table 4. DNA Methylation Changes in Early Onset Preeclampsia (EOPET) Versus Normal Controls (Norm).
Illumina Probe
Identifier PE,34 weeks Norm Combined pvalue
Combined adjusted
pvalue Chr Symbol
cg14696348 11 34 1.20E-11 3.32E-07 16 MC1R
cg10994126 46 65 5.59E-09 7.71E-05 1 PAPPA2
cg15271616 55 68 1.93E-08 0.000133122 9 RUSC2
cg09450238 24 39 1.38E-07 0.00054516 14 BTBD6
cg00503840 46 60 3.54E-07 0.000976753 7 DLX5
cg26304237 35 50 5.08E-07 0.00107717 1 DNAJC6
cg00410921 26 37 9.28E-07 0.001599147 15 CKMT1B
cg27360098 35 23 1.24E-06 0.001904068 7 ELN
cg02089348 48 58 2.40E-06 0.002470369 4 TMEM129
cg26954174 41 51 2.89E-06 0.002604173 16 CARD15
cg02110963 43 53 4.34E-06 0.003510057 6 MGC40222
cg03752885 32 42 4.27E-06 0.003510057 19 DAPK3
cg15503752 39 52 4.57E-06 0.003510057 17 ST6GALNAC1
cg18279742 40 54 5.57E-06 0.003941476 16 RPS2
cg18328334 29 39 6.66E-06 0.004477123 2 TNS1
cg19385139 40 51 7.15E-06 0.004587805 13 COL4A2
cg04502814 29 43 7.73E-06 0.004750353 5 SEPP1
cg00520135 62 72 1.57E-05 0.007208179 15 TPM1
cg11283860 51 62 3.46E-05 0.011779235 1 SLC45A1
cg07824742 69 57 3.77E-05 0.011815535 9 DBH
cg10045881 61 74 3.57E-05 0.011815535 1 CHI3L2
cg10590292 56 71 4.25E-05 0.01288429 12 BIN2
cg23917399 9 21 4.56E-05 0.013248486 5 TNFAIP8
cg04765277 53 68 6.26E-05 0.016138871 10 FLJ45983
cg12840719 36 47 6.33E-05 0.01615595 9 CDKN2A
% methylation levels for top 25 most highly significant differentially methylated CpG sites in EOPET (PE,34 weeks, n = 9) and normal controls (Norm, n = 24). Adjusted p
values are shown with FDR controlled at 10%. Full table of all 49 significant CpG sites is shown in Table S4A (in File S1).
doi:10.1371/journal.pone.0107318.t004
Table 5. DNA Methylation Changes in Late Onset Preeclampsia Versus Normal Controls.
Illumina Probe Identifier PE.34 weeks norm Combined pvalue Combined adj. pvalue Chr Symbol>
cg00250430 34 45 0.0003 0.0760 9 DMRT2
cg03214697 22 42 0.0007 0.0958 22 SEC14L4
cg04576021 67 56 0.0002 0.0746 6 HLA-DOB
cg21820677 12 24 0.0003 0.0760 4 GABRA2
cg25484904 67 77 0.0008 0.0982 4 FLJ21511
% methylation levels for late onset preeclampsia (PE.34 weeks, n = 14) and normal controls (norm, n = 24) are shown. Adjusted p values are shown with FDR controlled
at 10%.
doi:10.1371/journal.pone.0107318.t005
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CpG methylation within the P2RX4 promoter was reduced in
preeclampsia samples relative to controls in our data, suggesting
elevated transcription [31]. Similarly, a CpG site in the promoter
region of Pregnancy-Associated Plasma Protein A2 (PAPPA2),
whose expression is elevated in preeclampsia and is a promising
biomarker for its detection [32,33,34,35], exhibited reduced DNA
methylation in preeclampsia samples compared to normal
controls.
It is somewhat surprising that our gender-specific analysis of
preeclampsia-related changes in DNA methylation (Tables 2 and
3) identified significant differences in only pregnancies involving
female fetuses. Although there is no prior evidence that
preeclampsia-specific DNA methylation patterns are gender-
specific, there are numerous examples of gender-specific DNA
methylation, chromatin structure and gene expression patterns
involving autosomal loci. For example, it has been shown that
environmentally-dependent modifications of histone H3 are
sexually dimorphic in the developing mouse brain [36], and that
patterns of acetylation (but not methylation) can be masculinized
in females by testosterone in utero [37]. Furthermore, dimorphic
gene expression has been reported in liver, kidney, blastocysts,
lacrimal gland, placenta and brain [38,39,40,41,42] and sex-
specific methylation patterns have been previously characterized
[43,44].
It is not surprising that the inclusion of X chromosome-specific
data resulted in clear gender-dependent hierarchical clustering
patterns. Notably, when X chromosome data were removed,
samples were still broadly separated into gender-associated clusters
and statistically significant gender-dependent autosomal alter-
ations in DNA methylation were observed. These observations are
worthy of further study at higher resolution with a larger sample
size. The identification of autosomal origins of gender-specific
differences is significant because previous studies of DNA
methylation in preeclampsia have controlled for fetal gender by
Figure 3. Targeted Analysis of Fetal Gender-Specific Differences in Placental DNA Methylation. Locus-specific analysis of CpG
methylation was carried out by high-throughput bisufite sequencing. Statistically significant differences in% methylation between samples are
marked with **. Genomic coordinates corresponding to values on the x-axis can be found in Table S6B in File S1.
doi:10.1371/journal.pone.0107318.g003
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simply removing X chromosome specific probes from the analyses
[16,17]. Based on our observations, this approach may not be
sufficient to control for gender bias in DNA methylation.
In summary, we have undertaken a systematic analysis of
preeclampsia-associated DNA methylation changes in the placen-
ta. We identified a number of differentially methylated CpG sites
in tissues from preeclampsia patients including a number that were
altered only in EOPET cases compared to controls.
Supporting Information
Figure S1 Hierarchical clustering, with respect to
gestational age at delivery, of DNA patterns in placental
tissues from preeclampsia patients.
(TIF)
Figure S2 A. Hierarchical clustering, with respect to fetal
gender, of DNA patterns in placental tissues from preeclampsia
patients. B. MDS Analysis, with respect to fetal gender of DNA
patterns, in placental tissues from preeclampsia patients. C.
Hierarchical clustering with respect to fetal gender of DNA
patterns in placental tissues from normal controls. D. MDS
Analysis with respect to fetal gender of DNA patterns in placental
tissues from normal controls.
(TIFF)
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Without Control for Fetal Gender: CpG sites at which samples
from preeclampsia samples are more highly methylated than those
from normal controls are shown. Table S2B- Preeclampsia-
Associated Changes in Placental DNA Methylation Without
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Dependent Preeclampsia-Associated Changes in Placental DNA
Methylation: CpG sites at which samples from normal controls are
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Preeclampsia-Associated Changes in Placental DNA Methylation:
CpG sites at which samples from preeclampsia samples are more
highly methylated (,10%) than those from normal controls are
shown. Table S4A- DNA Methylation Changes in Early Onset
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EOPET (PE,34 weeks, n = 9) and normal controls (norm, n= 24).
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